DCTH
DCTH clinical trials: DELCATH SYSTEMS, INC.
Every trial on ClinicalTrials.gov where DELCATH SYSTEMS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 11
- As lead sponsor
- 2
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
DCTH on the catalyst calendar · DCTH registry changes
- Primary completion May 2029Sponsor estimatePhase 2NCT06875128Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved...Delcath Systems Inc. · Metastatic Breast Cancer in the LiverRecruitingDCTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06607458Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved...Delcath Systems Inc. · Refractory Metastatic Colorectal CancerRecruitingDCTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 18, 2023ActualPhase 3NCT02678572Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular MelanomaDelcath Systems Inc. · Ocular MelanomaCompletedDCTHLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2024Sponsor estimatePhase 3NCT05022901An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular MelanomaDelcath Systems Inc. · Metastatic Ocular MelanomaActive, not recruitingDCTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2018ActualPhase 2NCT02415036Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic...Delcath Systems Inc. · Hepatocellular CarcinomaTerminatedDCTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2023Sponsor estimatePhase 2/Phase 3NCT03086993Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic CholangiocarcinomaDelcath Systems Inc. · Bile Duct CancerUnknown statusDCTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2012ActualPhase 3NCT00324727Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to...Delcath Systems Inc. · Intraocular MelanomaCompletedDCTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2020Sponsor estimateNo phase registeredNCT03266042Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic MalignancyDelcath Systems Inc. · Hepatic Malignant Neoplasm Primary Non-ResectableUnknown statusDCTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2017ActualPhase 2NCT02406508Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCCDelcath Systems Inc. · Hepatocellular Carcinoma (HCC)WithdrawnDCTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT01728051Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to LiverDelcath Systems Inc. · Metastatic Liver CancerNo longer availableDCTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2012ActualPhase 2NCT00096083Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver CancerDelcath Systems Inc. · CancerCompletedDCTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2030Sponsor estimatePhase 1/Phase 2NCT07281924Hepzato Kit and Opdualag for Metastatic Melanoma and Liver MetastasisUniversity of Wisconsin, Madison · Metastatic MelanomaRecruitingDCTHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2030Sponsor estimatePhase 2NCT07276386Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute · Metastatic Uveal MelanomaRecruitingDCTHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner